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Abstract
Introduction Numerous factors contribute to uncertainty in
test measurement procedures, and this uncertainty can have
a significant impact on the downstream clinical utility and
cost-effectiveness of testing strategies. Currently, however,
there is no clear guidance concerning if or how such factors
should be considered within Health Technology Assess-
ments (HTAs) of tests.
Objective The aim was to provide an introduction to key
concepts in measurement uncertainty for the HTA com-
munity and to explore, via systematic review, current
methods utilised within HTAs.
Methods HTAs of in vitro tests including a model-based
economic evaluation were identified via the Centre for
Reviews and Dissemination (CRD) HTA database and key
reimbursement authority websites. Data were extracted to
explore the specific components of measurement uncer-
tainty assessed and methods utilised. The findings were
narratively synthesised.
Results Of 107 identified HTAs, 20 (19%) attempted to
assess components of measurement uncertainty: 15 did so
via some form of pre-model assessment (such as a litera-
ture review or laboratory survey); four also included
components within the economic model; and one consid-
ered measurement uncertainty within the model only. One
study quantified the impact of measurement uncertainty on
cost-effectiveness and found that this parameter signifi-
cantly changed the results, but did not impact the overall
decision uncertainty.
Conclusion A minority of HTAs identified from this
review used various approaches to assess and/or incorpo-
rate the impact of measurement uncertainty, indicating that
these assessments are feasible. Uncertainty remains around
best practice methodology for conducting such analyses;
further research is required to ensure that future HTAs are
fit for purpose.
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Key Points for Decision Makers
Variation in test measurement procedures can result
in systematic and/or random variation in test results
(i.e. measurement uncertainty).
This uncertainty can have a significant impact on the
clinical utility and cost-effectiveness of testing
strategies, but is not currently routinely considered
with Health Technology Assessments (HTAs).
A systematic review identified a minority of HTAs
(n = 20/107; 19%) that have used various approaches
to incorporate the impact of components of
measurement uncertainty within a pre-model
assessment (n = 19; such as a literature review or
laboratory survey) and/or within the economic model
(n = 5).
Uncertainty remains around best practice
methodology for conducting such analyses; further
research is required to ensure that future HTAs are fit
for purpose.
1 Background
All measurements are subject to uncertainty, whether it be
determining the distance between two objects, the level of
CO2 in the atmosphere or the pressure exerted within a
mechanical system. In vitro clinical tests are no exception.
The time of day a sample is taken, mode of sample
transportation and time between sample collection and
analysis are just a few examples of a multitude of factors
that can influence the concentration of substances within a
test sample, thereby altering the reported test value and
introducing uncertainty.
The consequence of this uncertainty is that any observed
test value may be different to the ‘true’ underlying target
value one wishes to measure. This can impact the clinical
accuracy of a test (the ability of a test to correctly identify
patients with and without a given condition) if measured
values are incorrectly observed as lying above or below the
test cut-off threshold used to determine disease classifica-
tions.1 If, as a consequence, a meaningful proportion of
patients receive inappropriate healthcare interventions,
patients’ health may be compromised and unnecessary
costs accrued. Understanding and quantifying the magni-
tude of test measurement uncertainty, as well as the sub-
sequent impact on downstream test outcomes, is therefore
critical in order to ensure that testing procedures are
implemented only when net health benefits are expected to
be obtained.
Across the developed world, the established gold-stan-
dard tool for informing evidence-based healthcare deci-
sions is the Health Technology Assessment (HTA): a
multidisciplinary process to systematically examine the
safety, efficacy and cost-effectiveness of new healthcare
interventions, and identify any social, organisational and
ethical issues concerning adoption [1, 2]. In response to the
growing importance of in vitro tests, many HTA and
reimbursement authorities now include such technologies
within their remit, and some institutions—such as the
National Institute for Health and Care Excellence (NICE)
in the UK—have established separate programmes of
assessment for tests distinct to pharmaceuticals [3, 4].
These assessments typically focus on three key domains:
(1) clinical accuracy—the ability of a test to correctly
identify patients with and without a given condition; (2)
clinical utility—the subsequent impact of a test on health
outcomes; and (3) cost-effectiveness—the ability of a test
to produce an efficient impact on health outcomes in
relation to healthcare expenditure.
The impact of measurement uncertainty within HTA
assessments is, in our experience, not routinely considered.
Indeed current guidance in this area is unclear: both NICE
in the UK and the Canadian Agency for Drugs and Tech-
nologies in Health (CADTH)—world leaders in technology
assessments—make no mention of measurement uncer-
tainty within their current methodology guidance, for
example [4, 5]. The Medical Services Advisory Committee
(MSAC) in Australia is the only authority we are aware of
that specifies the need to evaluate such evidence, using the
associated terminology of analytic validity [6]. However,
whilst stipulating that such data should be reviewed,
MSAC offer no recommendations regarding how these data
should be assessed or utilised within subsequent clinical
and economic assessments.
In order to establish if and how measurement uncer-
tainty is currently being addressed within HTAs, and in
particular within economic evaluations, a systematic
review of reports published by internationally recognised
HTA agencies [registered with the International Network
of Agencies for HTA (INAHTA)] and including an eco-
nomic decision model was conducted. In addition, for
readers unfamiliar with the field of measurement uncer-
tainty, a brief introduction to key concepts in the field is
first provided, focusing on the case of quantitative tests (i.e.
measuring the quantity or concentration of analyte within a
sample, typically assessed against a given disease cut-off
1 A simulated example of the impact of measurement uncertainty on
clinical accuracy is provided in the Electronic Supplementary
Material (Sect. 1).
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threshold).2 A corresponding table of relevant terminology
can be found in the Electronic Supplementary Material
(Sect. 2), and further key texts are recommended for
interested readers [7–10].
2 An Introduction to Measurement Uncertainty
2.1 Precision and Trueness
The central components of measurement performance are
precision [characterised by the absence of random error
(i.e. imprecision) in measurement] and trueness [the
absence of systematic error (i.e. bias) in measurement].
Increased imprecision and/or bias in measurement results
in increased measurement uncertainty.
Imprecision [expressed as a coefficient of variation
(CV)3 or standard deviation (SD)] is explored by observing
the degree of dispersion in repeated test measurements
[11–13]. The level of imprecision measured depends on
how many factors expected to affect test performance
(including time, operator, calibration, environment and
equipment) are altered during the measurement procedure.
Holding all factors constant (i.e. within-batch testing)
measures repeatability; altering one or more factors within
the same laboratory measures intermediate precision;
whilst conducting testing across different laboratories (in
which all factors would be expected to vary) measures
reproducibility.
Analysis of trueness meanwhile (typically assessed
according to % bias, regression analysis or difference
plots) relies on comparative analysis of results from the test
of interest (the index test) versus the ‘true’ target value. In
reality this ‘true’ value is unknown and must be estimated
using a specified reference test, ideally based on officially
validated test methods or samples of known composition
[but often also based on consensus data from external
quality assessment (EQA)4 schemes or established ‘gold
standard’ test results].5 Alternatively, new tests may be
compared against each other (without a reliably proxy for
the truth) in order to ascertain the level of between-test
discordance.
An important feature in the evaluation of trueness is test
selectivity: the ability of a test to identify the target analyte
of interest as opposed to other sample components.
Selectivity depends on the level of obstruction from sub-
stances in the test sample which either inhibit the process
of binding with the target analyte (i.e. interference) or are
mistaken for the target analyte, leading to ‘unintentional’
binding (i.e. cross-reactivity).
2.2 Pre-analytical, Analytical and Biological Factors
Both precision and trueness can be affected by numerous
factors along the testing pathway, including (1) biological
variation—fluctuations in the quantity of bodily fluids
within an individual over time; (2) variation in pre-ana-
lytical factors—processes occurring prior to the point of
sample analysis; and (3) variation in analytical factors—
processes occurring at the point of sample analysis. These
can be summarised in a ‘feather diagram’; the generalised
example illustrated in Fig. 1 shows key factors grouped by
category and following a (roughly) chronological order
from the initial test request through to obtaining the final
result.
2.3 Limits and Range
Various limits can be specified which determine the
boundaries against which testing is reasonably conducted.
These are (1) the limit of blank (LoB), defined as the
highest (apparent) quantity of analyte expected to be
identified when processing blank samples; (2) the limit of
detection (LoD), defined as the lowest quantity reliably
distinguish from the LoB; and (3) the limits of quantifi-
cation (LoQ), defined as the lower and upper quantities a
test can measure with a specified level of precision and
trueness. Identified limits are routinely used to inform the
reportable range of a test.
2.4 Summary Measures
Different elements of uncertainty, as illustrated in Fig. 1,
may be combined to estimate a summary measure of
uncertainty. Two main approaches to this end have been
adopted in the literature: total error (TE) and uncertainty of
measurement (UM). Briefly, TE is calculated as the linear
sum of bias and imprecision, in which imprecision is
multiplied by a ‘z factor’ to cover a required region of
confidence (e.g. at the 95% confidence level, TE = bias ?
1.96 * imprecision). UM on the other hand is a measure of
dispersion (i.e. SD), calculated by combining individual
2 Other types of tests include (a) semi-quantitative tests, based on
quantitative measurements which are subsequently grouped into a
number of discrete categories (e.g. high/medium/low risk) and
(b) qualitative tests, which may or may not be derived from
quantitative measurement and report whether or not an analyte/
feature is present (i.e. positive/negative result). The metrics of
measurement uncertainty adopted for (a) are much the same as for
quantitative tests (with potential extra complexity occurring due to the
addition of categories); whilst for (b) more simplified assessments are
typically required (see [10]).
3 CV = the ratio of the SD to the mean, multiplied by 100.
4 Also known as proficiency testing.
5 Note that these approaches may misrepresent bias if either the
major method adopted by participating laboratories in EQA schemes
or the gold-standard test are themselves inaccurate.
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uncertainties occurring along the testing pathway (e.g.
using propagation of error rules) multiplied by a ‘coverage
factor’ to similarly capture a specified region of confidence.
Whilst TE represents an upper bound on the level of
deviation from truth expected to occur in a given mea-
surement, UM defines a confidence interval around the
observed result that is expected to contain the true value.
Although there is an ongoing debate within the literature as
to the relative merits of each approach [14–17], within the
context of this study, both metrics are considered to be
viable measures of overall measurement uncertainty.
3 Methods
The review protocol was published in advance on the
PROSPERO database (CRD42017056778). The primary
source was the Centre for Reviews and Dissemination
(CRD)6 HTA database; this consists of completed and
ongoing HTAs from INAHTA-registered HTA authorities
(49 at the time of conducting the review)7 in addition to 20
other CRD-recognised HTA organisations, and includes
reports from national reimbursement authorities (e.g.
NICE) as well as publically funded research councils [e.g.
the UK National Institute for Health Research (NIHR)]. As
such it is a principle resource for HTAs expected to directly
influence national healthcare decisions.
A search strategy (see the Electronic Supplementary
Material, section 3) combining key terms on in vitro tests
and economic decision models was developed and run in
March 2017. All HTAs including a model-based economic
evaluation and evaluating an in vitro test (including diag-
nostic, screening, prognostic, predictive and monitoring
tests) across any disease area, human population or setting
and reported since 1999 with a full HTA report available in
English were included.
Records were managed using Endnote V 7.2 (Thompson
Reuters). All titles and abstracts were screened by a pri-
mary reviewer, and 10% were independently screened by a
secondary reviewer. Full papers were subsequently
screened by the primary reviewer only; any uncertainties
regarding inclusions were checked with the secondary
reviewer. For studies identified as including an assessment
of measurement uncertainty, data were extracted on the
specific components assessed and the methods utilised,
with 10% of data extraction independently checked by the
secondary reviewer. A broad definition of measurement
uncertainty was adopted, including all components listed in
Fig. 1, as well as data on TE, UM, limits (LoB, LoD and
LoQ), reportable range and test failure rates. Results were
narratively synthesised.
Fig. 1 Feather diagram depicting factors that may contribute to measurement uncertainty
6 Whilst the maintenance of other CRD databases (DARE and NHS
EED) ceased in 2015, the HTA database continued to be maintained
at the time of conducting this review and into 2018.
7 As per the INAHTA membership eligibility criteria, these are non-
profit organisations assessing healthcare technologies, relating to a
regional or national government, funded at least 50% by public
sources and providing free access to reports on request (see http://
www.inahta.org/).
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In addition to the HTA database, online records of key
reimbursement authorities expected to be the largest con-
tributors of relevant HTAs (NICE, CADTH and MSAC)
were cross-checked by the primary reviewer [18–20].
Citation checking of included studies was also conducted
to identify any further relevant HTAs.
4 Results
A total of 107 studies were included (see Fig. 2), and
agreement between reviewers at abstract screening was
good (k = 0.85).8 A summary of study characteristics is
provided in the Electronic Supplementary Material (sec-
tion 4). The majority of studies were conducted within the
UK (62%), followed by Canada (16%) and Australia
(14%), with a gradual rise in the frequency of annual HTA
publications since 1999.
Of the 107 identified HTAs, 71 (66%) did not evaluate
measurement uncertainty. Sixteen (15%) incorporated data
on test failure rates only (e.g. test failures included as an
item within a literature review and/or as a parameter within
the economic model) and were therefore of limited interest.
Twenty studies (19%) considered further components of
measurement uncertainty (see Table 1) [21–42]. The
majority of these were published from 2009 onwards, and
evaluated one or a small number of measurement uncer-
tainty components (including imprecision, trueness, bio-
logical variability and pre-analytical or analytical effects)
within some form of assessment prior to the economic
model, such as a literature review or laboratory survey.
These evaluations are henceforth denoted ‘pre-model
assessments’. Five studies incorporated measurement
uncertainty within the economic model itself: four in
addition to a pre-model assessment [22, 30, 31, 39]; one
within the model only [21]. These studies used a range of
techniques—including individual patient simulation and
Monte Carlo simulation—to incorporate data on test
agreement [39], biological and analytical variability
[21, 30, 31] or TE [22] (see Table 2).
5 Discussion
5.1 Review Findings
Despite limited guidance in this area, assessment of test
measurement uncertainty has been attempted in a minority
of HTAs (n = 20; 19%) indicating that such analyses are
feasible.
The majority of studies (n = 19) included measurement
uncertainty within some form of pre-model assessment,
such as a literature review or laboratory survey. Indeed the
frequency of these assessments appears to have been
increasing in recent years; this may reflect the fact that
more HTAs of tests are being conducted in general, a
growing awareness of the importance of measurement
uncertainty, and/or increasing availability of relevant data
upon which to base such evaluations. On the whole,
however, these studies were considered to be partial
assessments: most considered one or a limited set of
measurement uncertainty components and none formally
assessed (i.e. beyond a general discussion) the potential
quantitative impact of measurement uncertainty on clinical
accuracy or utility.
A small minority of studies (n = 5) utilised data on test
measurement uncertainty within the economic model. Of
those, the most recent (Stein et al. 2016) was not a direct
attempt to account for measurement uncertainty, but rather
the authors here utilised between-test discordance data as a
means of evaluating additional tests in the model [39].
Meanwhile the oldest study (Marks et al. 2000) is most
interesting as an example of what not to do [21]. Here the
authors simply set the proportion of false positive results
equal to a given level of biological and analytical vari-
ability (i.e. imprecision), which fails to account for the
dependence of test misclassifications on the position of
values relative to the test cut-off threshold. In contrast, the
approach taken by MSAC correctly accounted for this
dependency, by first assigning ‘true’ test values, simulating
the addition of measurement uncertainty to generate
observed values (in this case, using TE to define a confi-
dence interval around the true value),9 and then comparing
these results against the given cut-off threshold to deter-
mine the proportion of misdiagnoses [22]. Similarly the
more recent studies by Farmer et al. (2014) and Perera et al.
(2015) simulated the addition of uncertainty on top of
‘true’ baseline values; in this case also accounting for the
impact of uncertainty in the rate of baseline health and
disease progression within repeated testing scenarios using
regression analysis of longitudinal individual patient data
[30, 31]. A key drawback with this approach, however,
concerns the data and computational resources required,
which would likely pose challenges within typical HTA
timelines.
Only the MSAC study explicitly explored the impact of
variation in measurement uncertainty on cost-effectiveness
[22]. Here the authors found that, whilst variation in TE
8 Note all discrepancies were a result of the primary reviewer being
more inclusive than the secondary reviewer.
9 A key question for this study, however, concerns the validity of
using TE (which combines both random and systematic error) to
assign both sides of a confidence interval; assuming bias acts in a
fixed direction, for example, this approach will overestimate
uncertainty.
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Fig. 2 PRISMA flow diagram of search results. CADTH Canadian
Agency for Drugs and Technologies in Health, CRD Centre for
Reviews and Dissemination, DAP Diagnostics Assessment
Programme, HTA Health Technology Assessment, MSAC Medical
Services Advisory Committee, NICE National Institute for Health and
Care Excellence
A. F. Smith et al.
Table 1 Summary of HTA reports (n = 20) including components of measurement uncertainty in a pre-model assessment and/or the economic
decision model
Study Test characteristics Pre-model assessments Measurement
uncertainty
included in
economic
model?
POCT? Disease area Primary role
of test
Method Components of measurement uncertainty assessed
Marks et al.
2000
(UK) [21]
– Cardiology Screening – – Yes
MSAC
2001
(AUS)
[22]
POCT:
clinician-
led
Cardiology Prognosis Systematic
review
Trueness (% bias); precision (repeatability and
reproducibility); TE; analytical effects (site,
operator and sample type)
Yes
Gailly et al.
2009
(BEL)
[23]
POCT:
self-led
Haematology Monitoring Systematic
review
Precision (repeatability and intermediate); test
failures
–
Pearson
et al.
2010
(UK)
[24, 25]
POCT:
clinician-
led
Gastro Diagnosis Systematic
review
Biological variability; distribution in faeces;
faecal matrix; interference; stability; patient
compliance; normal range
–
MAS 2010
(CA) [26]
– Cancer Prognosis Systematic
review
Precision (intermediate and reproducibility); test
failures
–
Ward et al.
2013
(UK) [27]
– Cancer Prognosis Systematic
review
Precision (intermediate and reproducibility);
trueness (concordance)
–
Westwood
et al.
2014
(UK) [28]
– Cancer Predictive Systematic
review ?
survey
Proportion of tumour cells needed; test failures –
Westwood
et al.
2014
(UK) [29]
– Cancer Predictive Systematic
review ?
survey
Proportion of tumour cells needed; LoD; test
failures
–
Farmer
et al.
2014
(UK) [30]
– Diabetes Screening Analysis of
IPD
Biological and analytical variation Yes
Perera et al.
2015
(UK) [31]
– Cardiology Monitoring Analysis of
IPD
Biological and analytical variation Yes
Sharma
et al.
2015
(UK) [32]
POCT:
self-led
Haematology Monitoring Literature
review
Precision (reproducibility); trueness (r correlation
coefficient)
–
Nicholson
et al.
2015
(UK) [33]
– Cancer Diagnosis Systematic
review
Precision (intermediate and reproducibility);
trueness (recovery); LoB, LoD, LoQ;
interference; linearity; range; pre-analytical
effects; stability; test failures
–
MSAC
2015
(AUS)
[34, 35]
– Cancer Prognosis Literature
review
Selectivity –
Kessels
et al.
2015
(AUS)
[36]
– Pregnancy
care and
screening
Diagnosis Systematic
review
Selectivity; test failures –
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was not expected to alter the overall decision uncertainty
(since all results remained above the specified 100,000
Australian dollars (AUS$) cost-effectiveness threshold), it
was expected to have a significant impact on the base case
results (resulting in a 24% drop from AUS$133,934 to
AUS$101,419 per life year gained when reducing TE from
8% to 0%). This example clearly illustrates the potential
impact of measurement uncertainty on cost-effectiveness,
which could feasibly be of significant importance in sce-
narios exhibiting baseline results closer to the cost-effec-
tiveness threshold.
5.2 Future Research
Whilst this review has identified previous HTA assess-
ments of measurement uncertainty, outstanding uncertain-
ties and issues require consideration before general
guidance in this area can be feasibly implemented. For pre-
model assessments, future studies would benefit from
(currently lacking) guidance on best practice methods to
conduct, synthesise and report literature reviews of mea-
surement uncertainty, as well as appropriate methodology
for utilising data from alternative resources (e.g. laboratory
surveys, EQA reports and pathology studies). For eco-
nomic evaluations, future case studies could explore par-
ticular considerations of interest including the following:
the relative importance of various components of mea-
surement uncertainty for different kinds of tests (e.g.
diagnostic vs monitoring; laboratory vs point of care test;
quantitative vs qualitative etc.); the use of alternative
summary measures versus individual components of mea-
surement uncertainty; and the feasibility of different
approaches. In addition, outside the scope of HTAs, we are
aware of several studies that have utilised Monte Carlo
simulation methods to explore the impact of measurement
uncertainty on clinical accuracy as a means of identifying
test analytical performance goals (i.e. maximum allowable
imprecision and/or bias in order to maintain clinical
Table 1 continued
Study Test characteristics Pre-model assessments Measurement
uncertainty
included in
economic
model?
POCT? Disease area Primary role
of test
Method Components of measurement uncertainty assessed
Harnan
et al.
2015
(UK) [37]
POCT:
self-led
Other
(asthma)
(1)
Diagnosis,
(2)
monitoring
Systematic
review
Trueness (Bland-Altman analysis, correlation
coefficients); test failures
–
Freeman
et al.
2015
(UK) [38]
– Cancer Monitoring Systematic
review
Trueness (Bland-Altman analysis, Deming
regression); test failures
–
Stein et al.
2016
(UK) [39]
– Cancer Prognosis Pathology
study
Trueness (Kappa statistic, discordance) Yes
Hay et al.
2016
(UK) [40]
POCT:
clinician-
led
Other
(urology)
Diagnosis Clinical
study
Trueness (Kappa statistic); test failures –
Freeman
et al.
2016
(UK) [41]
– Gastro Monitoring Systematic
review
Trueness (Bland-Altman analysis, Cohen’s
Kappa); test failures
–
Auguste
et al.
2016
(UK) [42]
– Infection
(TB)
Diagnosis Systematic
review
Trueness (Kappa statistic, discordance); test
failures
–
Further details of modelling studies provided in Table 2
AUS Australia, BEL Belgium, CA Canada, Gastro gastroenterology, HTA Health Technology Assessment, LoB limit of blank, LoD limit of
detection, LoQ limits of quantification, MAS Medical Advisory Secretariat, MSAC Medical Services Advisory Committee, POCT point of care
test, TB Tuberculosis, TE total error, UK United Kingdom
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accuracy) [43–46]; extending HTA evaluations to include
similar assessments (which could feasibly be based on cost-
effectiveness outputs in addition to clinical accuracy) is
another potential avenue for exploration in future studies,
which could further extend the clinical impact of HTAs.
5.3 Strengths and Limitations
This review focused on reports from INAHTA-registered
and CRD-recognised HTA authorities, which are expected
to reflect best practice methodologies and directly influence
healthcare reimbursement and adoption decisions. Taking a
broader perspective and considering all kinds of evidence
which may inform healthcare decision making (e.g. stand-
alone cost-effective assessments) would likely yield addi-
tional findings of interest; as may expanding the search to
before 1999 (although the majority of relevant studies
identified were from 2009 onwards) and non-English lan-
guages. Nevertheless, this is the first systematic review of
its kind, which highlights both advances and issues in
current approaches to HTAs and can help to inform the
direction of future research and guidance in this area.
Furthermore, whilst the focus of this study was on in vitro
tests, many of the issues here highlighted will be of rele-
vance to pharmacological studies utilising tests as surro-
gate outcome measures, as well as evaluations of imaging
and in vivo technologies.
6 Conclusions
Various approaches have been adopted within a minority of
HTAs to assess test measurement uncertainty. Further
research is required to identify best practice methodology
for conducting such analyses and to ensure that future
HTAs are fit for purpose.
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